Management of Prolonged Prothrombin Time
Assessment and Initial Management
- For a patient with a prolonged prothrombin time, active bleeding should be assessed, and the underlying cause, such as anticoagulant therapy, liver disease, or vitamin K deficiency, should be determined, with consideration of other coagulation parameters like fibrinogen levels and platelet count 1, 3
- The American Society of Anesthesiologists recommends assessing for microvascular oozing, which suggests inadequate hemostasis, before administering treatment 1
Treatment Options Based on Clinical Scenario
- The American College of Cardiology recommends Fresh Frozen Plasma (FFP) at a dose of at least 15 ml/kg for immediate correction when bleeding is present, with higher doses of 30 ml/kg recommended for active bleeding or severe coagulopathy 1, 2
- For anticoagulant-induced prolongation, Prothrombin Complex Concentrate (PCC) is recommended for rapid reversal, with doses of 25 units/kg for INR 2-4, 35 units/kg for INR 4-6, and 50 units/kg for INR >6 4
- For non-anticoagulant causes, FFP remains the mainstay of treatment, with a dose of 15-30 ml/kg depending on severity, and a target of PT correction to <1.5 times normal control 1, 2, 5
Special Considerations
- For traumatic bleeding with coagulopathy, a goal-directed approach using standard laboratory parameters should be followed, with consideration of a 1:1:1 ratio of RBC:FFP:platelets for massive hemorrhage, and early administration of tranexamic acid if fibrinolysis is suspected 1, 3
- For patients with liver disease, higher volumes of FFP may be needed due to dysfunctional fibrinogen production, and platelet count should be maintained >75 × 10^9/L 1
- For patients requiring neurosurgery, PT/aPTT should be maintained <1.5 times normal control, and point-of-care testing (TEG/ROTEM) should be considered to guide therapy if available 5
Monitoring and Follow-up
- After FFP administration, clinical response and repeat PT measurement should be assessed to evaluate the effectiveness of treatment 1
- Delaying treatment in actively bleeding patients while awaiting laboratory confirmation should be avoided, and underdosing FFP (doses <15 ml/kg) is often inadequate 1, 3